Biomarker Profiles in Psychosis Risk Groups Within Unaffected Relatives Based on Familiality and Age.
cognition
eye tracking
family history
first-degree relatives
polygenic risk score
psychotic disorders
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
08 07 2021
08 07 2021
Historique:
pubmed:
12
3
2021
medline:
17
12
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Investigating biomarkers in unaffected relatives (UR) of individuals with psychotic disorders has already proven productive in research on psychosis neurobiology. However, there is considerable heterogeneity among UR based on features linked to psychosis vulnerability. Here, using the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) dataset, we examined cognitive and neurophysiologic biomarkers in first-degree UR of psychosis probands, stratified by 2 widely used risk factors: familiality status of the respective proband (the presence or absence of a first- or second-degree relative with a history of psychotic disorder) and age (within or older than the common age range for developing psychosis). We investigated biomarkers that best differentiate the above specific risk subgroups. Additionally, we examined the relationship of biomarkers with Polygenic Risk Scores for Schizophrenia (PRSSCZ) in a subsample of Caucasian probands and healthy controls (HC). Our results demonstrate that the Brief Assessment of Cognition in Schizophrenia (BACS) score, antisaccade error (ASE) factor, and stop-signal task (SST) factor best differentiate UR (n = 169) from HC (n = 137) (P = .013). Biomarker profiles of UR of familial (n = 82) and non-familial (n = 83) probands were not significantly different. Furthermore, ASE and SST factors best differentiated younger UR (age ≤ 30) (n = 59) from older UR (n = 110) and HC from both age groups (age ≤ 30 years, n=49; age > 30 years, n = 88) (P < .001). In addition, BACS (r = -0.175, P = .006) and ASE factor (r = 0.188, P = .006) showed associations with PRSSCZ. Taken together, our findings indicate that cognitive biomarkers-"top-down inhibition" impairments in particular-may be of critical importance as indicators of psychosis vulnerability.
Identifiants
pubmed: 33693883
pii: 6161524
doi: 10.1093/schbul/sbab013
pmc: PMC8266584
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1058-1067Subventions
Organisme : NIMH NIH HHS
ID : R25 MH101078
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Biol Psychiatry. 2012 May 15;71(10):881-9
pubmed: 22401986
Biol Psychiatry. 2015 Jan 15;77(2):127-36
pubmed: 24923619
Schizophr Res. 2009 Apr;109(1-3):24-37
pubmed: 19223268
Schizophr Res. 2015 Aug;166(1-3):310-5
pubmed: 26008884
Schizophr Res. 2007 Sep;95(1-3):54-60
pubmed: 17656071
Sci Rep. 2016 Sep 01;6:32597
pubmed: 27581658
Schizophr Bull. 2014 Sep;40(5):1011-21
pubmed: 24080895
Am J Psychiatry. 2013 Nov;170(11):1275-84
pubmed: 23771174
Psychiatry Res. 2019 Mar;273:422-429
pubmed: 30684787
Neuropsychopharmacology. 2016 Apr;41(5):1241-50
pubmed: 26354046
Schizophr Bull. 2016 Jul;42(4):984-91
pubmed: 26873889
Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):921-930
pubmed: 30635714
Transl Psychiatry. 2019 Sep 17;9(1):230
pubmed: 31530798
JAMA Psychiatry. 2016 Dec 01;73(12):1239-1248
pubmed: 27806157
Schizophr Res. 2014 Nov;159(2-3):491-8
pubmed: 25261042
Schizophr Res. 2013 Jul;147(2-3):301-9
pubmed: 23664588
Transl Psychiatry. 2018 Apr 12;8(1):78
pubmed: 29643358
Age (Dordr). 2011 Jun;33(2):219-27
pubmed: 20811950
PLoS One. 2013;8(3):e57962
pubmed: 23483953
Transl Psychiatry. 2017 Oct 24;7(10):e1249
pubmed: 29064472
Am J Psychiatry. 2016 Oct 1;173(10):989-996
pubmed: 27363511
Schizophr Res. 2016 Jul;174(1-3):192-196
pubmed: 27197903
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Psychophysiology. 2014 Apr;51(4):348-57
pubmed: 24660885
Biol Psychiatry. 2008 Dec 15;64(12):1051-9
pubmed: 18701089
Biol Psychiatry. 2009 Dec 1;66(11):988-9
pubmed: 19900610
Biol Psychiatry. 2006 Jul 1;60(1):32-9
pubmed: 16603134
Am J Psychiatry. 2013 Aug;170(8):886-98
pubmed: 23771210
Am J Psychiatry. 2016 Apr 1;173(4):373-84
pubmed: 26651391
Transl Psychiatry. 2016 Oct 18;6(10):e924
pubmed: 27754483
Cogn Neuropsychiatry. 2013;18(1-2):44-82
pubmed: 22998599
Am J Psychiatry. 2016 Oct 1;173(10):980-988
pubmed: 27363508
Am J Med Genet B Neuropsychiatr Genet. 2018 Jan;177(1):21-34
pubmed: 28851104
Psychiatry Res. 2017 Feb;248:105-110
pubmed: 28038438
J Abnorm Psychol. 1994 May;103(2):277-87
pubmed: 8040497
Am J Med Genet B Neuropsychiatr Genet. 2015 Jul;168B(5):392-401
pubmed: 25963331
Arch Gen Psychiatry. 1984 Feb;41(2):157-61
pubmed: 6696597
Am J Psychiatry. 2013 Nov;170(11):1263-74
pubmed: 23846857
Schizophr Bull. 2012 Nov;38(6):1268-76
pubmed: 22290265
Schizophr Bull. 2014 Mar;40 Suppl 2:S131-7
pubmed: 24562492
Iran J Psychiatry. 2016 Jan;11(1):15-23
pubmed: 27252764
Biol Psychiatry. 2006 Jul 1;60(1):1-10
pubmed: 16368076
Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):285-93
pubmed: 17853391
Arch Gen Psychiatry. 2010 Jun;67(6):578-88
pubmed: 20530007
Biol Psychiatry. 2003 Jan 1;53(1):25-38
pubmed: 12513942
Schizophr Res. 2006 Oct;87(1-3):172-80
pubmed: 16737801
Nat Protoc. 2020 Sep;15(9):2759-2772
pubmed: 32709988
Neuroimage. 2005 Oct 1;27(4):960-8
pubmed: 16009570
Neuropsychobiology. 2012;66(2):93-9
pubmed: 22814285
Am J Psychiatry. 2013 Nov;170(11):1285-96
pubmed: 24185241
Neuropsychiatr Dis Treat. 2018 Dec 05;14:3339-3348
pubmed: 30584307
J Psychiatr Res. 2012 Jan;46(1):105-10
pubmed: 22056319